Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.

Trial Profile

Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DAHHS
  • Most Recent Events

    • 31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Dec 2015 Results published in the Journal of Hepatology
    • 10 Nov 2015 Sub-study results (n = 12) published in the AIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top